Ruxolitinib treatment permits lower cumulative glucocorticoi
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Ruxolitinib appears to be an effective medication for lowering inflammation markers and regulating body temperature. This study aimed to analyze the effects of ruxolitinib on children with secondary hemophagocytic lymphohistiocytosis (HLH).

11 pediatric patients diagnosed with HLH and treated with ruxolitinib (ruxolitinib group: group R) were retrospectively analyzed. 11 age-matched pediatric patients with HLH undergoing conventional treatment during the same period were also analyzed.

--In group R, 3 patients who did not respond to methylprednisolone (MP) pulse and IV immunoglobulin (IVIG) therapies were treated with Ruxolitinib and their temperature decreased to normal levels.

--4 patients had normal temperature after conventional treatment (dexamethasone and etoposide, with or without cyclosporine A), but they had severe organ involvement, including obvious yellowing of the skin, increased liver enzyme levels and neuropsychiatric symptoms, and they were all ameliorated with ruxolitinib treatment.

--4 patients were relieved with ruxolitinib therapy alone. In group C, the body temperatures of 11 patients decreased to normal levels after conventional treatment.

--The body temperature of group R patients decreased to normal levels more rapidly than that of group C patients.

--The glucocorticoid dosage in group R was significantly lower than that in group C. Both groups were followed-up for 2–2.5 years.

--No obvious adverse drug reactions to ruxolitinib were observed during treatment and follow-up.

Finally, Ruxolitinib may be a viable alternative to glucocorticoid therapy for the treatment of HLH in infants, reducing or eliminating glucocorticoid-related side effects.